Overview

DNA Vaccine for Ragweed Allergic Adults

Status:
Completed
Trial end date:
2001-08-21
Target enrollment:
Participant gender:
Summary
Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity and immunogenicity have either decreased, or increased in tandem, with no resultant efficacy: safety benefit ratio. This study utilizes an adjuvant approach in which synthetic immunostimulatory DNA is conjugated to ragweed allergen in an attempt to modulate both the clinical and immunologic allergic response to ragweed exposure in ragweed-allergic patients with seasonal rhinitis.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University